Amarna Therapeutics, a privately-held biotechnology company developing gene therapies in a range of rare and prevalent diseases, has announced the appointment of Aurelia Caparrós as the Company’s new Chief Business Officer (CBO), effective 1st of April 2024.
Aurelia brings more than 25 years of healthcare industry experience with expertise in business development, strategy and global marketing including P&L responsibilities spanning diverse geographies.
She has held global leadership roles for Novartis, led multiple enterprise transformation programmes and implemented strategic growth initiatives to achieve business goals while fostering the culture of inclusion and enterprise mindset.
As the new CBO, she will be responsible for driving Amarna's future growth and expansion, both in the Netherlands and Spain.
Her key responsibilities will include identifying assets, companies, and areas of interest, designing tailored partnering structures and securing attractive deals through the entire deal-making process.
Aurelia will also play a crucial role in promoting Amarna as the partner of choice at business partnering meetings and scientific conferences, as well as supporting the company's investor relations and fundraising activities.
"We are thrilled to welcome Aurelia Caparrós as our new Chief Business Officer," said Henk Streefkerk, CEO and Medical Director of Amarna Therapeutics BV. "Her leadership and deep industry expertise will be invaluable as we continue to expand our business and bring our transformative gene therapies to patients in need."
